Recent News

• 03.30.2026 - A New Era of Blood Clot Care — How CAVT Technology Could Democratize PE Treatment
• 03.26.2026 - Employee Spotlight: Gabriel M. Vieira
• 03.25.2026 - Penumbra Presents Results for STORM-PE and STRIKE-PE, Adding to a Growing Body of Evidence Backing CAVT
• 03.05.2026 - Case Study: Next-Generation Lightning Flash 3.0 Efficiently Clears Right-Sided PE and Lower Extremity Venous Thrombus
• 03.02.2026 - EVT Panel Discussion: Expert Perspectives on the Modern PE Landscape
• 02.25.2026 - Penumbra, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results
• 02.25.2026 - Employee Spotlight: Mary Karam

Recent Filings

• 03.27.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 03.17.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.17.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.17.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.17.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.04.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.03.2026 - 425 Prospectuses and communications, business combinations
• 03.02.2026 - 144 Report of proposed sale of securities
• 02.25.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 02.25.2026 - EX-99.1 EX-99.1